Line 183: | Line 183: | ||
<thead> | <thead> | ||
<tr> | <tr> | ||
− | <th></th> | + | <th>anti-GC4N(suntag) scFv</th> |
− | <th></th> | + | <th>anti-flag scFv</th> |
− | <th></th> | + | <th>anti-IL-15 scFv</th> |
− | <th></th> | + | <th>anti-HER2 scFv</th> |
− | <th></th> | + | <th>NL domains through cytoplasmic</th> |
</tr> | </tr> | ||
</thead> | </thead> | ||
<tbody> | <tbody> | ||
<tr> | <tr> | ||
− | <td data-label=""></td> | + | <td data-label="anti-GC4N(suntag) scFv"><a href="http://parts.igem.org/Part:BBa_K3132007" target="_blank">(BBa_K3132007)</a></td> |
− | <td data-label=""></td> | + | <td data-label="anti-flag scFv"><a href="http://parts.igem.org/Part:BBa_K3132009" target="_blank">(BBa_K3132009)</a></td> |
− | <td data-label=""></td> | + | <td data-label="anti-IL-15 scFv"><a href="http://parts.igem.org/Part:BBa_K3132008" target="_blank">(BBa_K3132008)</a></td> |
− | <td data-label=""></td> | + | <td data-label="anti-HER2 scFv"><a href="http://parts.igem.org/Part:BBa_K3132005" target="_blank">(BBa_K3132005)</a></td> |
− | <td data-label=""></td> | + | <td data-label="NL domains through cytoplasmic"><a href="http://parts.igem.org/Part:BBa_K3132006" target="_blank">(BBa_K3132006)</a></td> |
</tr> | </tr> | ||
</tbody> | </tbody> | ||
Line 202: | Line 202: | ||
<thead> | <thead> | ||
<tr> | <tr> | ||
− | <th></th> | + | <th>STAT3 transcription factor</th> |
− | <th></th> | + | <th>pSTAT promoter</th> |
− | <th></th> | + | <th>PIP-Elk1 transcription factor</th> |
− | <th></th> | + | <th>PIP-Elk1 promoter</th> |
− | <th></th> | + | <th>4×UAS</th> |
+ | <th>CAR-IL-2-His tag</th> | ||
</tr> | </tr> | ||
</thead> | </thead> | ||
<tbody> | <tbody> | ||
<tr> | <tr> | ||
− | <td data-label=""></td> | + | <td data-label="STAT3 transcription factor"><a href="http://parts.igem.org/Part:BBa_K3132010" target="_blank">(BBa_K3132010)</a></td> |
− | <td data-label=""></td> | + | <td data-label="pSTAT promoter"><a href="http://parts.igem.org/Part:BBa_K3132011" target="_blank">(BBa_K3132011)</a></td> |
− | <td data-label=""></td> | + | <td data-label="PIP-Elk1 transcription factor"><a href="http://parts.igem.org/Part:BBa_K3132012" target="_blank">(BBa_K3132012)</a></td> |
− | <td data-label=""></td> | + | <td data-label="PIP-Elk1 promoter"><a href="http://parts.igem.org/Part:BBa_K3132013" target="_blank">(BBa_K3132013)</a></td> |
− | <td data-label=""></td> | + | <td data-label="4×UAS"><a href="http://parts.igem.org/Part:BBa_K3132014" target="_blank">(BBa_K3132014)</a></td> |
+ | <td data-label="CAR-IL-2-His tag"><a href="http://parts.igem.org/Part:BBa_K3132015" target="_blank">(BBa_K3132015)</a></td> | ||
</tr> | </tr> | ||
</tbody> | </tbody> | ||
Line 221: | Line 223: | ||
<thead> | <thead> | ||
<tr> | <tr> | ||
− | <th></th> | + | <th>human interleukine 15(IL-15)</th> |
− | <th></th> | + | <th>8×suntag</th> |
− | <th></th> | + | <th>8×flag</th> |
− | <th></th> | + | <th>synNotch-anti-HER2</th> |
− | <th></th> | + | <th>Cetuximab scFv-CAR</th> |
+ | <th>trastuzumab4D5-5 scFv-CAR</th> | ||
</tr> | </tr> | ||
</thead> | </thead> | ||
<tbody> | <tbody> | ||
<tr> | <tr> | ||
− | <td data-label=""></td> | + | <td data-label="human interleukine 15(IL-15)"><a href="http://parts.igem.org/Part:BBa_K3132017" target="_blank">(BBa_K3132017)</a></td> |
− | <td data-label=""></td> | + | <td data-label="8×suntag"><a href="http://parts.igem.org/Part:BBa_K3132018" target="_blank">(BBa_K3132018)</a></td> |
− | <td data-label=""></td> | + | <td data-label="8×flag"><a href="http://parts.igem.org/Part:BBa_K3132019" target="_blank">(BBa_K3132019)</a></td> |
− | <td data-label=""></td> | + | <td data-label="synNotch-anti-HER2"><a href="http://parts.igem.org/Part:BBa_K3132020" target="_blank">(BBa_K3132020)</a></td> |
− | <td data-label=""></td> | + | <td data-label="Cetuximab scFv-CAR"><a href="http://parts.igem.org/Part:BBa_K3132021" target="_blank">(BBa_K3132021)</a></td> |
+ | <td data-label="trastuzumab4D5-5 scFv-CAR"><a href="http://parts.igem.org/Part:BBa_K3132022" target="_blank">(BBa_K3132022)</a></td> | ||
</tr> | </tr> | ||
</tbody> | </tbody> |
Revision as of 11:18, 21 October 2019
Our favorite basic part - GEMS
This part is a highly generalizable synthetic receptor that has a wild sensing of input signals and effective activation of gene expression. As developed in 2015, this receptor still contains much possibility for transformation in synthetic biology. Our team determined to use this receptor, make some transformation as interest and give it a new mission in our nanobots WuKong.
Structure and mechanism of GEMS
GEMS is a dimer of two subunits, each was constructed by three domains, an extracellular domain as an anti-suntag scFv, a scaffold transmembrane domain derived from EpoR (erythropoietin receptor) and a FGFR1(fibroblast growth factor receptor 1) intracellular domain that induces MAPK pathway (Figure 1a). When the MAPK-GEMS recognizes the ligand, each receptor subunit will rotate around its own axis for about 100°, leads to an activation of transcription factor PIP-Elk which then modulate expression of reporter gene (Figure 1b).
![smmu_demonstrate_1](https://static.igem.org/mediawiki/2019/5/53/T--SMMU-China--parts_basicparts_1.png)
See more
Integrated information about GEMS posted on Demonstrate page, we also put the characterizations of GEMS on the Registry of Standard Biological Parts website, welcome to check part (BBa_K3132016) on its page.
Here we listed other basic parts we have constructed below.
Gal4-VP64 | ZF43-8-VP64 | ZF21-16-VP64 | PIP-VP64 | MinimalCMV |
---|---|---|---|---|
(BBa_K3132000) | (BBa_K3132001) | (BBa_K3132002) | (BBa_K3132003) | (BBa_K3132004) |